Abstract
Somatostatin receptors are highly expressed in almost all meningiomas but in this setting their functional role is not clear. A 59-yrold woman had been treated with octreotide after an unsuccessful operation for a GH-secreting pituitary adenoma. After 8 yr of treatment, a nuclear magnetic resonance (NMR) scan disclosed a 3 cm meningioma of the tentorium. Mean GH was 2.2 ng/ml and IGF-I 325 ng/ml. Meningioma was resected and tissue was digested to obtain tumor cell suspension. Aim of the study was to measure epidermal growth factor (EGF)-induced proliferation of cultured meningioma cells in the presence of either somatostatin or octreotide. Cells were grown to semiconfluency in Dolbecco’s modified eagle medium (D-MEM) supplemented with 10% fetal calf serum (FCS). After 48 h in D-MEM without serum, the medium was replaced by fresh medium plus recombinant EGF (10 ng/ml) and somatostatin or octreotide were added in the final concentrations of 1,10 and 100 nM. 20 h later 1 μcgCi of 3H-thymidine was added to each well. After 4 h, incorporated radioactivity was measured. While octreotide did not influence significantly cell growth at the three dose tested, somatostatin increased thymidine incorporation dose-dependently (peak 100nM: 150%±27% vs medium plus EGF, p<0.05). Octreotide effectively suppressed GH secretion in our acromegalic patient but is unlikely that its long-term use could have stimulated the growth of meningioma since it did not significantly influence the in vitro proliferation of the meningioma cells. These results suggest that somatostatin-mediated proliferative effect on meningioma cells is not mediated by the subtype 2 of the somatostatin receptor.
Similar content being viewed by others
References
Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999, 20: 157–198.
Weckbecker G., Raulf F., Stolz B., Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther. 1993, 60: 245–264.
Giustina A., Zaltieri G., Negrini F., Wehrenberg W.B. The pharmacological aspects of the treatment of acromegaly. Pharmacol. Res. 1996, 34: 247–268.
Tulipano G., Bonfanti C., Milani G., et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinol. 2001, 73: 344–351.
Krenning E.P., Kwekkwboom D.J., Bakker W.H. Somatostatin receptor scintigraphy with [111-DTPA-D-Phe] and [123Tyr3]-octretide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993, 20: 716–723.
Reubi J.C., Maurer R., Klijn J.G.M., et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J. Clin. Endocrinol. Metab. 1986, 63: 433–438.
Dutour A., Kumar U., Panetta R., et al. Expression of so-matostatin receptor subtypes in human brain tumors. Int. J. Cancer 1998, 76: 620–627.
Schultz S., Pauli S.U., Schulz S., et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype SSTR2A. Clin. Cancer Res. 2000, 6: 1865–1874.
Kunert-Radek J., Stepien H., Radek A., Pawlikowski M. Somatostatin suppression of meningioma cell proliferation in vitro. Acta Neurol. Scand. 1987, 75: 434–436.
Koper J.W., Markstein R., Kohler C., et al. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J. Clin. Endocrinol. Metab. 1992, 74: 543–547.
Barkan A.L., Lloyd R.V., Chandler W.F., et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J. Clin. Endocrinol. Metab. 1988, 67: 1040–1048.
Kraenzlin M.E., CH’ng J.C.G., Wood S.M., Carr D.H. Long-term treatment of VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985, 88: 185–187.
Weckebecker G., Tolcsvai L., Stolz B., Pollack M., Bruns C. Somatostatin analogue octreotide enhances the antineo-plastic effect of tamoxifen and ovariectomy on 7, 12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res. 1994, 54: 6334–6337.
Runzi M.W., Jaspers C., Windeck R., et al. Successful treatment of meningioma with octreotide. Lancet 1989, 1 (8646): 1074.
Garcia-Luna P.P., Relimpio F., Pumar A., et al. Clinical use of octreotide in unresectable meningiomas. A report of three cases. J. Neuro. Sci. 1993, 37: 237–241.
Jaffrain-Rea M.L., Minniti G., Santoro A., et al. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin. Neurol. Neurosurg. 1998, 100: 40–43.
Orme S.M., Mcnally R.J.Q., Cartwright R.A., Belchetz P.A. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab. 1998, 83: 2730–2734.
Jenkins P.J., Frajese V., Jones A.M., et al. Insulin-like growth factor I and the development of colorectal neo-plasia in acromegaly. J. Clin. Endocrinol. Metab. 2000, 85: 3218–3221.
Cannav`o S., Curt`o L., Fazio R., et al. Coexistance of growth-hormone secreting pituitary adenoma and in-tracranial meningioma: a case report and review of the literature. J. Endocrinol. Investig. 1993, 16: 703–708.
Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumori-genesis and neoplastic growth. Endocr. Rev. 2000, 21: 215–144.
Kurihara M., Tokunaga Y., Tsutsumi K., et al. Characterization of insulin-like growth factor-I and epidermal growth factor receptors in meningioma. J. Neurosurg. 1989, 71: 538–544.
Tsutsumi K., Kitigawa N., Niwa M., Himeno A., Taniyama K., Shibata S. Effect of suramin on 125I-IGF-I binding to human meningiomas and on proliferation of meningioma cells. J. Neurosurg. 1994, 80: 502–509.
Antoniades H.N., Galanopoulos T., Neville-Golden J., Maxwell M. Expression of insulin-like growth factors-I and II and their receptors mRNAs in primary human astrocy-tomas and meningiomas: in vitro studies using in vitro hybridization and immunocytochemistry. Int. J. Cancer 1992, 50: 215–222.
Lichtor T., Kurpakus M.A., Gurney M.E. Expression of insulin-like growth factors and their receptors in human meningiomas. J. Neuro-oncol. 1993, 17: 183–190.
Friend K.E., Radinski R., McCutcheon I.E. Growth hormone receptor expression and function in meningioma: effects of a specific receptor antagonist. J. Neurosurg. 1999, 91: 93–99.
McCutcheon I.E., Flyvbjerg A., Hill H., et al. Antitumor activity of the growth hormone receptor antagonist pegvi-somant against human meningiomas in nude mice. J. Neurosurg. 2001, 94: 487–492.
Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 2000, 85: 526–529.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
De Menis, E., Tulipano, G., Villa, S. et al. Development of a meningioma in a patient with acromegaly during octreotide treatment: Are there any causal relationships?. J Endocrinol Invest 26, 359–363 (2003). https://doi.org/10.1007/BF03345185
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345185